Phase 1 N=20 PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer
Peritoneal Carcinomatosis · Ovarian Cancer Stage IIIB · Ovarian Cancer Stage IIIC
Primary: Maximally Tolerated Dose (MTD) of Abraxane — 0; 0; 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=24 Pharmacokinetic Study of Oral ALXN1840 in Japanese and Non-Japanese Adult Healthy Participants
Wilson Disease
Primary: Area Under The Plasma Concentration Versus Time Curve From Time 0 (Dosing) To The Last Quantifiable Concentration (AUCt) Of Plasma Total Molybdenum After Each Dose…
Phase 1 N=14 Study of Milademetan in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) Following Administration of Milademetan in Participants With Relapsed or Refractory Acute Myeloid Leukemia…
Phase 1 N=24 A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Participants With Moderate or Severe Hepatic Impairment (HI) and Normal Hepatic Function
Hepatic Impairment · Healthy Volunteers
Primary: Cmax: Maximum Observed Plasma Concentration for Mobocertinib and Its Active Metabolites (AP32960 and AP32914) — 9.67; 11.3; 10.5; 3.88 nanograms per milliliter (ng/mL)
Phase 1 N=23 A Study of Pevonedistat in Adult East Asian Participants
Leukemia, Myeloid, Acute · Myelodysplastic Syndromes
Primary: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 3; 7; 3; 10 Participants
Phase 1 N=10 Clavulanic Acid (CLAV) and Cocaine Interaction Safety Study
Cocaine Dependence · Cocaine Addiction · Cocaine Abuse
Primary: Number of Participants With Severe Adverse Events (AEs) — 0; 0; 0; 0 Participants
Phase 1 N=24 Evaluate the Pharmacokinetics, Safety, and Tolerability of Nirsevimab in Healthy Chinese Adults
Evaluate PK Profile
Primary: Serum Concentrations of Nirsevimab — NA; 27.644; 41.794; 43.811 micrograms/milliliter (mcg/mL)
Phase 1 N=40 Clinical Trial Intelligent Biometrics for PTSD - Clinical Trial
PTSD
Primary: Post Traumatic Stress Disorder Symptom Severity - Clinician Rated — 25.71; 32.00 units on a scale
Phase 1 N=51 A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.
Breast Cancer · Prostate Cancer · Ovarian Cancer
Primary: Percentage of Participants With Adverse Events — 100; 100; 100; 100 percentage of participants
Phase 1 N=477 Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)
Solid Tumor
Primary: Overall Response Rate (ORR) — 4.3; 20.0; 0.0; 30.4 Percentage of Participants
Phase 1 N=73 Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis
Systemic Lupus Erythematosus · Rheumatoid Arthritis
Primary: Number of Participants With Dose-Limiting Toxicity (DLT) — 0; 0; 0; 0 Participants
Phase 1 N=8 Tenofovir Rectal Douche to Prevent HIV Transmission Among Adolescents (ATN DREAM)
HIV/AIDS · HIV Prevention
Primary: Tenofovir Diphosphate (TFV-DP) Concentration — 2441; 3472; 406 femtomole/million cells
Phase 1 N=12 Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)
Urinary Bladder Neoplasms
Primary: Number of Grades 1-5 Adverse Events — 12; 3; 15; 9 adverse events
Phase 1 N=28 Impact of Weekly Administration of Rifapentine and Isoniazid on Steady State Pharmacokinetics of Tenofovir Alafenamide in Healthy Volunteers (YODA)
Healthy Volunteers
Primary: Plasma Area Under the Curve (AUC) for Tenofovir Alafenamide (TAF) During the Dosing Interval of 0 to 24 Hours (AUC0-24hr) — 295.5; 472.1; 248.1 hr*ng/ml
Phase 1 N=32 First in Human Study of RVP-001, a New Manganese Based MRI Contrast Agent
Healthy
Primary: Pharmacokinetic (PK) Parameter Cmax — 264; 685; 992; 1960 nmol/mL